The Muscle Peptide Pitch: Separating “Studied” From “Proven”

Somewhere between the gym locker room and an Instagram ad, someone convinced you that a vial could do what years of squats have not. IGF-1 LR3, MK-677, CJC-1295, follistatin 344. The copy always sounds confident. The evidence, once you actually go looking for it, sounds a lot less so.

This is not a takedown of the whole category. Some of these compounds are genuinely interesting research subjects. But “interesting research subject” and “proven muscle builder you can buy safely online” are two very different claims, and the marketing collapses them into one on purpose. Worth untangling before any money changes hands.

Seven names, two mechanisms, one shopping-cart illusion

“Peptides for muscle growth” reads like a single product category. It isn’t. Under that label sit seven compounds: IGF-1 LR3, follistatin 344, MK-677 (also marketed as ibutamoren), ipamorelin, CJC-1295, GHRP-6, and hexarelin. Selling copy treats them as interchangeable variants of the same idea. Mechanistically, they split into two camps.

The first camp works the growth hormone axis: pituitary releases growth hormone, growth hormone tells the liver to make IGF-1, IGF-1 does the actual signaling to tissue. MK-677, ipamorelin, CJC-1295, GHRP-6, and hexarelin are all growth hormone secretagogues or releasing peptides, meaning they nudge your own pituitary to put out more GH, which lifts IGF-1 downstream. IGF-1 LR3 skips that whole relay and is a modified version of the end hormone itself.

The second camp targets myostatin, the biological brake on muscle growth. Remove the brake in animals and muscle grows dramatically. That’s the entire premise behind follistatin 344, which blocks myostatin. Keep that “in animals” qualifier close. It matters more than the sales copy wants it to.

The gap the marketing never mentions

Here’s the distinction that actually decides whether any of this is worth your money: raising a hormone on a lab panel is trivial to demonstrate. Turning that hormonal bump into durable, functional muscle a person can actually use in daily life is a much higher bar, and it’s a bar most of these compounds simply haven’t cleared in controlled human research.

A compound can move growth hormone two-fold, five-fold, ten-fold, and still do nothing measurable for strength. That’s not hypothetical. It’s what the best human trial in this entire category actually found.

Who these compounds were tested on (hint: probably not you)

Read the actual trial populations and the target audience narrows fast. The genuine clinical interest in growth hormone secretagogues and myostatin blockers has centered on older adults losing lean mass and patients with muscle-wasting disease, not healthy 30-year-olds chasing an extra ten pounds on the bar. The data was generated in a different population answering a different question. Applying it to a gym goal is an extrapolation, not a conclusion.

And if you compete in a tested sport, the conversation ends before it starts. Growth hormone secretagogues, releasing peptides, and IGF-1 itself are on the World Anti-Doping Agency’s prohibited list at all times, in and out of competition, at any dose, by any route [7]. Ibutamoren (MK-677), ipamorelin, hexarelin and the other GHRPs, IGF-1 and its analogues, all named specifically [7]. A “research use only” sticker does not change your test result.

Compound by compound: what’s studied versus what’s proven

Here is the honest tier for each, stripped of marketing language.

MK-677 (ibutamoren) has the strongest human evidence in the category, and the finding is deflating rather than exciting. A two-year randomized, placebo-controlled trial in healthy older adults found it raised growth hormone and IGF-1 and increased fat-free mass by about 1.1 kg versus a loss of roughly half a kilo on placebo [1]. Then the sentence that should recalibrate every expectation you walked in with: that extra fat-free mass “did not result in changes in strength or function” [1]. Studied for two years, in a real trial, and the mass gained didn’t translate to anything a person could feel or use.

CJC-1295 raises growth hormone two- to ten-fold and IGF-1 one-and-a-half to three-fold in healthy adults, with elevated IGF-1 persisting for days [2]. That’s real, replicated hormone movement. It is not muscle-growth evidence. The trial measured hormones, not tissue or strength.

Ipamorelin is billed as the “clean,” selective option. The foundational work is animal data [4]. There is no substantial human trial showing it adds muscle in healthy adults. Selective is a real property. Proven-for-muscle is not one of its properties yet.

Hexarelin is a potent releaser, producing growth hormone output roughly double that of the natural releasing hormone across several administration routes in healthy volunteers [5]. Strong hormonal signal, no controlled human muscle data, and a documented tendency to lose potency with repeated use.

GHRP-6 has a long track record for raising growth hormone and a well-known side effect of driving appetite. The literature is about hormone kinetics, not muscle outcomes in healthy people.

IGF-1 LR3 is, on paper, the most direct lever, since it is the downstream hormone itself, modified to last longer. In practice there are essentially no controlled human muscle trials on it. There is, however, a genuine safety signal to weigh: large prospective human data tie higher circulating IGF-1 to increased risk of several cancers, including breast and prostate [6]. Elevating that specific signal deliberately, above what your body regulates on its own, is not a small decision to wave off.

Follistatin 344 carries the most inflated claims of the seven. The actual human evidence comes from gene therapy, not an injectable peptide. In a phase 1/2a trial, a follistatin gene-therapy construct was delivered into the thigh muscles of Becker muscular dystrophy patients, and some improved walking distance with muscle growth confirmed on biopsy [3]. That’s a real, promising result, in sick patients, using gene transfer. It says nothing about whether a follistatin peptide injection builds muscle in a healthy gym-goer. Anyone conflating those two is either confused or selling something.

Line them all up and the pattern repeats: reliable hormone elevation, thin-to-absent human proof of actual muscle gain, and in the one case where a two-year trial actually measured strength, it found none. The marketing timeline is years ahead of where the science actually sits.

If you’re still considering this category, here’s the actual decision

Once you accept that the compounds cluster around “interesting, mechanistically plausible, largely unproven for healthy-adult muscle gain, and mostly not FDA-approved,” arguing over which peptide is superior stops being the useful question. The variable that changes your actual risk isn’t the molecule. It’s whether a licensed clinician is anywhere in the loop.

There are really only two markets here, and they share vocabulary but nothing else. One is licensed telehealth: a clinician reviews history and bloodwork, prescribes when it’s appropriate, a licensed pharmacy compounds it, someone follows up. The other is research-chemical retail: a checkbox claiming “not for human consumption,” a powder in the mail, zero screening, zero accountability for what’s actually in the vial. Most search results for this category point to the second market.

Oversight matters more here than in most supplement categories, for two concrete reasons already on the table: these compounds act on the same IGF-1 pathway tied to cancer risk in large human cohort data [6], and the entire category is banned in competitive sport [7]. A research-chemical checkout will not tell you either of those things. A clinician will.

If you decide to go forward anyway, do it through supervision. FormBlends is one example of that structure: physician-reviewed, prescription-based access through licensed compounding pharmacies, with explicit acknowledgment that these are not FDA-approved finished drugs. Whichever provider you use, look for that same shape: real clinician, real prescription, licensed pharmacy, honest framing of what the compound is and isn’t.

The bottom line

None of these seven compounds has strong controlled human evidence for building meaningful, functional muscle in a healthy adult. The best-studied one gained lean mass over two years with zero measurable strength benefit [1]. Most are not FDA-approved for this use. The entire category is banned in tested sport [7]. That’s not a reason to feel cheated, it’s simply the information the sales page left out.

The better question isn’t which peptide to buy. It’s who you’d trust to advise you on one, if at all. A checkout page with a research-only disclaimer isn’t an answer to that question. A licensed clinician willing to tell you where the evidence actually stands, is.

Questions people actually ask

Does any peptide in this category actually build muscle in a healthy adult? The controlled human evidence is thin to nonexistent. Hormone elevation is well documented for the releasers, and myostatin blockade is dramatic in animal studies, but no compound here has strong trial data showing durable, functional muscle gain in healthy people. The best-studied one, MK-677, added lean mass over two years without any measurable gain in strength or function [1].

Which one has the most human data behind it? MK-677 (ibutamoren), and the result is sobering, not encouraging. Its two-year randomized, placebo-controlled trial in healthy older adults showed a rise in growth hormone and IGF-1 and about 1.1 kg of added fat-free mass, but “did not result in changes in strength or function” [1]. If the most rigorously tested compound in the category can’t move strength, that should temper expectations for the rest of the lineup.

Are these legal, and are any FDA-approved? Most are not approved as finished drugs for muscle building, and many are sold strictly as “research chemicals” with no clinical oversight attached. The more defensible path is a prescription from a licensed clinician, filled by a licensed compounding pharmacy, not a vial from an unregulated online seller.

Will using these get me flagged in drug testing? For a tested athlete, yes. Growth hormone secretagogues, releasing peptides, IGF-1, and its analogues sit on WADA’s prohibited list at all times, any dose, any route [7]. MK-677, ipamorelin, hexarelin, other GHRPs, and IGF-1 are all named explicitly [7]. “Research use only” packaging offers no exemption.

Why does the cancer question keep coming up around IGF-1? Because large prospective human cohort data link higher circulating IGF-1 to elevated risk across several cancers, including breast and prostate [6]. IGF-1 is exactly the pathway these compounds are designed to push, and IGF-1 LR3 pushes it most directly. That’s a real reason medical screening and follow-up belong in this conversation, not an optional add-on.

Does follistatin 344 actually do what the ads claim? Not as sold. The legitimate human evidence is a phase 1/2a gene-therapy trial in Becker muscular dystrophy patients, where a follistatin construct injected into the thigh produced improved walking distance and biopsy-confirmed muscle growth in some participants [3]. That’s a meaningful result in a sick population using gene delivery, entirely different from a peptide injection in a healthy adult at the gym.

If someone wants to pursue this anyway, what’s the safer route? Put a licensed clinician between yourself and the compound, not a shopping cart. That means someone reviewing history and bloodwork, prescribing only when warranted, using a licensed compounding pharmacy, and following up over time. FormBlends is one example offering physician-reviewed, prescription-based access through licensed pharmacies, transparent that these remain non-FDA-approved compounds. The structure of oversight is the point, not any particular name on the label.

References

1. Nass R, Pezzoli SS, Oliveri MC, et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.” Ann Intern Med. 2008;149(9):601-611. PMID 18981485. https://pubmed.ncbi.nlm.nih.gov/18981485/
2. Teichman SL, Neale A, Lawrence B, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
3. Mendell JR, Sahenk Z, Malik V, et al. “A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.” Mol Ther. 2015;23(1):192-201. PMID 25322757.
4. Raun K, Hansen BS, Johansen NL, et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998;139(5):552-561. PMID 9849822.
5. Ghigo E, Arvat E, Gianotti L, et al. “Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.” J Clin Endocrinol Metab. 1994;78(3):693-698. PMID 8126144.
6. Knuppel A, Fensom GK, Watts EL, et al. “Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK Biobank.” Cancer Res. 2020;80(18):4014-4021. PMID 32709735.
7. WADA Prohibited List S2, peptide hormones, growth factors and related substances (lists ibutamoren/MK-677, ipamorelin, hexarelin/GHRPs, IGF-1 and analogues, prohibited at all times).